Evidence map›Paper›PMID 30395776›Full record

ArticleGut microbes2019

Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels.

Rosica Valcheva, Petya Koleva, Inés Martínez, Jens Walter, Michael G Gänzle, Levinus A Dieleman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut microbes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 4 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 4 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Prebiotics for induction and maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. The effects of inulin on gut microbial composition: a systematic review of evidence from human studies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Inulin may inhibit ADAM17 to delay atherosclerosis.Open medicine (Warsaw, Poland) · 2026
    Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rosica Valchevaa Department of Medicine, Center of Excellence for Gastrointestinal Inflammation and Immunity Research, 7-142 Katz Group Centre , University of Alberta , Edmonton , Canada.
Petya Kolevab Department of Dentistry, 7-096 Katz Group Centre , University of Alberta , Edmonton , Canada.
Inés Martínezc Department of Agricultural, Food and Nutritional Science, 4-126A Li Ka Shing Centre for Health Research Innovation , University of Alberta , Edmonton , Canada.
Jens Walterc Department of Agricultural, Food and Nutritional Science, 4-126A Li Ka Shing Centre for Health Research Innovation , University of Alberta , Edmonton , Canada.
Michael G Gänzlee Department of Agricultural, Food and Nutritional Science, 4-10 Agriculture/Forestry Centre , University of Alberta , Edmonton , Canada.ORCID 0000-0003-0972-928X
Levinus A Dielemana Department of Medicine, Center of Excellence for Gastrointestinal Inflammation and Immunity Research, 7-142 Katz Group Centre , University of Alberta , Edmonton , Canada.
University of Alberta · CA

Funding

CIHR MOP-81396
6 · The paper itself

Abstract

The intestinal microbiota is involved in ulcerative colitis (UC) pathogenesis. Prebiotics are hypothesized to improve health through alterations to gut microbiota composition and/or activity. Our aim was therefore to determine if inulin-type fructans induce clinical benefits in UC, and identify if benefits are linked to compositional and/or functional shifts of the luminal (fecal) and mucosal (biopsy) bacterial communities. Patients (n = 25) with mild/moderately active UC received 7.5 g (n = 12) or 15 g (n = 13) daily oral oligofructose-enriched inulin (Orafti®Synergy1) for 9 weeks. Total Mayo score, endoscopic activity and fecal calprotectin were assessed. Fecal and mucosal bacterial communities were characterized by 16S rRNA tag sequencing, and short chain fatty acids (SCFA) production were measured in fecal samples. Fructans significantly reduced colitis in the high-dose group, with 77% of patients showing a clinical response versus 33% in the low-dose group (

Indexed as

AdolescentAdultAgedBacteriaColitis, UlcerativeColonFatty Acids, VolatileFecesFemaleFructansGastrointestinal MicrobiomeHumansInulinMaleMiddle AgedPilot ProjectsFatty Acids, VolatileFructansInulinPrebioticsRNA, Ribosomal, 16SbutyrateFOSfructansintestinal microbiotainulinpyrosequencingUlcerative colitis

Identifiers

PMID30395776
PMCPMC6546336
OpenAlexW2899648148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.